1NE Stock Overview
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Verrica Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.58 |
52 Week High | US$6.60 |
52 Week Low | US$2.60 |
Beta | 1.87 |
1 Month Change | -6.15% |
3 Month Change | -18.21% |
1 Year Change | -24.30% |
3 Year Change | -59.82% |
5 Year Change | -53.55% |
Change since IPO | -73.15% |
Recent News & Updates
Recent updates
Shareholder Returns
1NE | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 2.7% | 2.6% | 1.4% |
1Y | -24.3% | -24.2% | 7.5% |
Return vs Industry: 1NE matched the German Pharmaceuticals industry which returned -24.2% over the past year.
Return vs Market: 1NE underperformed the German Market which returned 7.5% over the past year.
Price Volatility
1NE volatility | |
---|---|
1NE Average Weekly Movement | 10.3% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1NE's share price has been volatile over the past 3 months.
Volatility Over Time: 1NE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 100 | Ted White | https://www.verrica.com |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
Verrica Pharmaceuticals Inc. Fundamentals Summary
1NE fundamental statistics | |
---|---|
Market cap | €196.66m |
Earnings (TTM) | -€62.00m |
Revenue (TTM) | €4.74m |
41.5x
P/S Ratio-3.2x
P/E RatioIs 1NE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1NE income statement (TTM) | |
---|---|
Revenue | US$5.12m |
Cost of Revenue | US$18.46m |
Gross Profit | -US$13.34m |
Other Expenses | US$53.66m |
Earnings | -US$66.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.58 |
Gross Margin | -260.28% |
Net Profit Margin | -1,307.47% |
Debt/Equity Ratio | 216.9% |
How did 1NE perform over the long term?
See historical performance and comparison